欢迎来到OAJRC平台!

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据:

Open Access Article

International Journal of Clinical Research. 2021; 5: (4) ; 15-19 ; DOI: 10.12208/j.ijcr.20210041.

Dyslipidemia and OSA
血脂代谢异常与OSA

作者: 李艺然, 任骏*,

复旦大学附属中山医院心内科 上海心血管病研究所 上海

*通讯作者: 任骏,单位:复旦大学附属中山医院心内科 上海心血管病研究所 上海;

发布时间: 2021-11-10 总浏览量: 210

摘要

阻塞性睡眠呼吸暂停(OSA)是一种常见疾病,与冠心病、心律失常、高血压等心血管疾病(CVD)的风险增加相关。因为它与已知的心血管危险因素密切相关,包括肥胖、血脂异常、交感神经活动增强、胰岛素抵抗、氧化应激等。流行病学和临床研究表明,血脂代谢异常的发生发展与OSA关系密切,可能形成恶性循环:一方面,OSA促进脂代谢紊乱,引起总胆固醇、三酰甘油(TG)、脂蛋白(LDL、HDL)等含量异常,这可能导致动脉粥样硬化,增加患心脏病的风险;另一方面,血脂代谢异常者,特别是血脂控制较差者,常常会出现OSA、影响睡眠。本文将基于相关研究,探讨血脂代谢异常与OSA之间的关系,为未来血脂代谢异常及CVD的治疗提供新的策略。

关键词: 血脂代谢异常;睡眠;阻塞性睡眠呼吸暂停;持续正压通气治疗;褪黑素;交感神经系统

Abstract

Obstructive sleep apnea (OSA) is a common disease associated with an increased risk of cardiovascular disease (CVD) such as coronary heart disease, arrhythmias and hypertension. Because it closely correlates with cardiovascular risk factors, including obesity, dyslipidemia, increased sympathetic activity, insulin resistance, oxidative stress, etc.Epidemiological and clinical studies have shown that the development of dyslipidemia is closely related to OSA, and may form a vicious circle. On the one hand, OSA promotes lipid metabolic disturbance, causingabnormal levels of totalcholesterol,triacylglycerol (TG) and lipoprotein (LDLand HDL), which may lead to atherosclerosis as well as increase the risk of heart disease; on the other hand, people with abnormal lipid metabolism, especially in poor lipid control, often suffer from OSA and have sleep disorders.Based on relevant studies, this review will discuss the relationship between dyslipidemia and OSA, and may provide new strategies for futuretreatment of dyslipidemia and CVD.

Key words: Dyslipidemia; Sleep; Obstructive sleep apnea (OSA); Continuous positive airway pressure (CPAP); Melatonin;Sympathetic nervous system

参考文献 References

[1] Heinzer R., Vat S., Marques-Vidal P., et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study[J]. The Lancet Respiratory Medicine. 2015;3(4):310-8.

[2] Yeghiazarians Y., Jneid H., Tietjens J. R., et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association[J]. Circulation. 2021;144(3):e56-e67.

[3] Tietjens J. R., Claman D., Kezirian E. J., et al. Obstructive Sleep Apnea in Cardiovascular Disease: A Review of the Literature and Proposed Multidisciplinary Clinical Management Strategy[J]. J Am Heart Assoc. 2019; 8(1): e010440.

[4] Javaheri S., Barbe F., Campos-Rodriguez F., et al. Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences[J]. J Am Coll Cardiol. 2017;69(7):841-58.

[5] Zhao X., Li X., Xu H., et al. Relationships between cardiometabolic disorders and obstructive sleep apnea: Implications for cardiovascular disease risk[J]. J Clin Hypertens (Greenwich). 2019;21(2):280-90.

[6] Stelmach-Mardas M., Mardas M., Iqbal K., et al. Dietary and cardio-metabolic risk factors in patients with Obstructive Sleep Apnea: cross-sectional study[J]. PeerJ. 2017;5:e3259.

[7] Lattimore J. D., Celermajer D. S., Wilcox I. Obstructive sleep apnea and cardiovascular disease[J]. J Am Coll Cardiol. 2003;41(9):1429-37.

[8] Chapman N., Chen C. Y., Fujita T., et al. Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension?[J]. J Hypertens. 2010; 28(9): 1796-803.

[9] Iesato K., Tatsumi K., Saibara T., et al. Decreased lipoprotein lipase in obstructive sleep apnea syndrome[J]. Circ J. 2007;71(8):1293-8.

[10] Can M., Açikgöz Ş, Mungan G., et al. Serum cardiovascular risk factors in obstructive sleep apnea[J]. Chest. 2006;129(2):233-7.

[11] Li J., Savransky V., Nanayakkara A., et al. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia[J]. J Appl Physiol (1985). 2007;102(2):557-63.

[12] Zanotti I., Potì F., Cuchel M. HDL AND REVERSE CHOLESTEROL TRANSPORT IN HUMANS AND ANIMALS: LESSONS FROM PRE-CLINICAL MODELS AND CLINICAL STUDIES[J]. Biochim Biophys Acta Mol Cell Biol Lipids. 2021:159065.

[13] Tan K. C., Chow W. S., Lam J. C., et al. HDL dysfunction in obstructive sleep apnea[J]. Atherosclerosis. 2006; 184(2): 377-82.

[14] Feres M. C., Fonseca F. A., Cintra F. D., et al. An assessment of oxidized LDL in the lipid profiles of patients with obstructive sleep apnea and its association with both hypertension and dyslipidemia, and the impact of treatment with CPAP[J]. Atherosclerosis. 2015; 241(2): 342-9.

[15] Karkinski D., Georgievski O., Dzekova-Vidimliski P., et al. Obstructive Sleep Apnea and Lipid Abnormalities[J]. Open Access Maced J Med Sci. 2017;5(1):19-22.

[16] Adedayo A. M., Olafiranye O., Smith D., et al. Obstructive sleep apnea and dyslipidemia: evidence and underlying mechanism[J]. Sleep Breath. 2014;18(1):13-8.

[17] Wu S. A., Kersten S., Qi L. Lipoprotein Lipase and Its Regulators: An Unfolding Story[J]. Trends Endocrinol Metab. 2021;32(1):48-61.

[18] Wood I. S., de Heredia F. P., Wang B., et al. Cellular hypoxia and adipose tissue dysfunction in obesity[J]. Proc Nutr Soc. 2009;68(4):370-7.

[19] Drager L. F., Jun J., Polotsky V. Y. Obstructive sleep apnea and dyslipidemia: implications for atherosclerosis[J]. Curr Opin Endocrinol Diabetes Obes. 2010;17(2):161-5.

[20] Barros D., García-Río F. Obstructive sleep apnea and dyslipidemia: from animal models to clinical evidence[J]. Sleep. 2019;42(3).

[21] Li J., Thorne L. N., Punjabi N. M., et al. Intermittent hypoxia induces hyperlipidemia in lean mice[J]. Circ Res. 2005;97(7):698-706.

[22] Roche O., Deguiz M. L., Tiana M., et al. Identification of non-coding genetic variants in samples from hypoxemic respiratory disease patients that affect the transcriptional response to hypoxia[J]. Nucleic Acids Res. 2016; 44(19): 9315-30.

[23] Prabhakar N. R., Kumar G. K., Peng Y. J. Sympatho- adrenal activation by chronic intermittent hypoxia[J]. J Appl Physiol (1985). 2012;113(8):1304-10.

[24] Bartels N. K., Börgel J., Wieczorek S., et al. Risk factors and myocardial infarction in patients with obstructive sleep apnea: impact of beta2-adrenergic receptor polymorphisms[J]. BMC Med. 2007;5:1.

[25] Reiter R. J., Tan D. X., Rosales-Corral S., et al. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives[J]. Mini Rev Med Chem. 2013;13(3):373-84.

[26] Zhang H. M., Zhang Y. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions[J]. J Pineal Res. 2014;57(2):131-46.

[27] Rong B., Wu Q., Reiter R. J., et al. The Mechanism of Oral Melatonin Ameliorates Intestinal and Adipose Lipid Dysmetabolism Through Reducing Escherichia Coli-Derived Lipopolysaccharide[J]. Cell Mol Gastroenterol Hepatol. 2021.

[28] Xu H., Yi H., Guan J., et al. Effect of continuous positive airway pressure on lipid profile in patients with obstructive sleep apnea syndrome: a meta-analysis of randomized controlled trials[J]. Atherosclerosis. 2014; 234(2): 446-53.

[29] Dorkova Z., Petrasova D., Molcanyiova A., et al. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome[J]. Chest. 2008;134(4):686-92.

[30] Cuhadaroğlu C., Utkusavaş A., Oztürk L., et al. Effects of nasal CPAP treatment on insulin resistance, lipid profile, and plasma leptin in sleep apnea[J]. Lung. 2009; 187(2): 75-81.

[31] Barceló A., Miralles C., Barbé F., et al. Abnormal lipid peroxidation in patients with sleep apnoea[J]. Eur Respir J. 2000; 16(4): 644-7.

[32] Barnaś M., Maskey-Warzęchowska M., Bielicki P., et al. Diurnal and nocturnal serum melatonin concentrations after treatment with continuous positive airway pressure in patients with obstructive sleep apnea[J]. Pol Arch Intern Med. 2017;127(9):589-96.

[33] Robinson G. V., Pepperell J. C., Segal H. C., et al. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials[J]. Thorax. 2004; 59(9): 777-82.

[34] Michailidis V., Steiropoulos P., Nena E., et al. Continuous positive airway pressure treatment: effect on serum lipids in patients with obstructive sleep apnoea[J]. Open Cardiovasc Med J. 2011;5:231-8.

[35] 邓华聪, 临床内科杂志刘东方 %J. 肥胖症与脂质代谢[J]. 2003(03):116-8.

[36] Kobayashi J., Nohara A., Kawashiri M. A., et al. Serum lipoprotein lipase mass: clinical significance of its measurement[J]. Clin Chim Acta. 2007;378(1-2):7-12.

[37] 杨秀颖, 张莉, 陈熙, et al. 2型糖尿病周围神经病变机制研究进展[J]. 2016(5):598-602.

[38] Szmyd B., Rogut M., Białasiewicz P., et al. The impact of glucocorticoids and statins on sleep quality[J]. Sleep Med Rev. 2021;55:101380.

引用本文

李艺然, 任骏, 血脂代谢异常与OSA[J]. 国际临床研究杂志, 2021; 5: (4) : 15-19.